These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7838036)

  • 21. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
    Chan BS; Dawson AH; Buckley NA
    Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
    Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
    Chládková J; Hak J; Martínková J; Chládek J
    Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced dose folinic acid rescue after rapid high-dose methotrexate clearance is not associated with increased toxicity in a pediatric cohort.
    Niinimäki R; Aarnivala H; Banerjee J; Pokka T; Vepsäläinen K; Harila-Saari A
    Support Care Cancer; 2022 Jan; 30(1):127-133. PubMed ID: 34235555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies.
    Mao J; Zhang L; Shen H; Tang Y; Song H; Zhao F; Xu W
    Neoplasma; 2014; 61(1):77-82. PubMed ID: 24195512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of methotrexate given intrathecally to children with acute lymphoblastic leukemia.
    Skibińska L; Daszkiewicz P; Michalewska D; Radwańska U
    Pol J Pharmacol Pharm; 1988; 40(2):135-43. PubMed ID: 3237563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics.
    Slørdal L; Kolmannskog S; Moe PJ; Prytz PS; Aarbakke J
    Pediatr Hematol Oncol; 1987; 4(1):33-42. PubMed ID: 3152911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
    J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
    Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
    Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Studies of methotrexate pharmacokinetics in children with neoplasms of the hematopoietic system after administration of different doses of the drug].
    Wysocki M; Krzyzanowski M; Ozyński T; Pilecki O; Balcar-Boroń A; Szadujkis-Szadurski L
    Acta Haematol Pol; 1992; 23(3):179-83. PubMed ID: 1492542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
    Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
    Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.